Magna-Lab moves to NASDAQ's OTC board

Article

The stock of niche MRI developer Magna-Lab has been moved to NASDAQ's OTC Bulletin Board due tothe company's failure to meet minimum listing requirements onNASDAQ's Small-Cap exchange. Magna-Lab, of Hicksville, NY, hopesto return to the small-cap market

The stock of niche MRI developer Magna-Lab has been moved to NASDAQ's OTC Bulletin Board due tothe company's failure to meet minimum listing requirements onNASDAQ's Small-Cap exchange. Magna-Lab, of Hicksville, NY, hopesto return to the small-cap market after securing additional fundinglater this year, according to vice president John Haytaian.

Magna-Lab failed to meet NASDAQ's net worth requirement of$1 million for the small-cap market after a private equity placementfell through late last year and the company began using debt tofund operations (SCAN 12/14/94). NASDAQ made the decision to moveMagna-Lab's stock earlier this month. Ironically, Magna-Lab'sstock began moving upward after the move, Haytaian said.

Magna-Lab signed a letter of intent this month for a secondarypublic offering of $5 million to take place in the next two tothree months that will bring the company back into compliancewith NASDAQ requirements. The firm may also complete a privateequity placement by then, according to Haytaian.

The company has been rounding out its stable of distributionpartners for the Magna-SL 0.3-tesla scanner, which received Foodand Drug Administration clearance last year (SCAN 9/28/94). Magna-Labthis month signed an agreement with American Medical Concepts(AMCI) of Houston to distribute Magna-SL to the U.S. orthopedicmarket. The deal will complement an agreement with Beta-Numericsfor the fee-per-scan and mobile markets, as well as a deal withElscint for international sales that has not yet been finalized.

Magna-Lab this month completed the first installation of Magna-SLto MedCenter Imaging in San Antonio, TX. The installation tookonly two days, Haytaian said. Imaging services firm Health Imagesof Atlanta will be under contract by Magna-Lab to provide servicefor that unit, he said.

Recent Videos
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
Related Content
© 2025 MJH Life Sciences

All rights reserved.